Pharmaceutical Executive November 8, 2023
The online promotion of intravenous infusions and oral forms of subanesthetic ketamine for the treatment of mental health conditions has been found to frequently carry misleading or false information.
Experts have raised concerns regarding online direct-to-consumer (DTC) advertising of subanesthetic ketamine, specifically the promotion of intravenous (IV) infusions and oral forms of ketamine for the treatment of mental health conditions.
In a study published by JAMA Network Open, the authors noted that IV ketamine has not been approved by the FDA to treat mental health issues and is used off-label, whereas the oral forms of the drug are unapproved compounded formulations that are frequently promoted for recreational purposes.
“Oral formulations are compounded, unapproved drugs often advertised to induce a hallucinogenic...
Today's Sponsors
Today's Sponsor